Stent position is more important than α-blockers or anticholinergics for stent-related lower urinary tract symptoms after ureteroscopic ureterolithotomy: A prospective randomized study

Korean Journal of Urology

Volumn 51, Issue 9, 2010, Pages 636-641

  Lee, Sun Ju ^a   Yoo, Changhee ^a   Oh, Cheol Young ^a   Lee, Yong Seong ^a   Cho, Sung Tae ^a   Lee, Seong Ho ^a   Yang, Dae Yul ^a   Lee, Sang Kon ^a   Cho, Jin Seon ^a  

^a Hallym University   (South Korea)

Author keywords

Adrenergic alpha antagonists; Cholinergic antagonists; Ureteroscopy; Urinary catheterization; Urological manifestations

Indexed keywords

TAMSULOSIN; TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIZZINESS; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; INDWELLING CATHETER; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; URETEROLITHOTOMY; URETEROSCOPY; VISUAL ANALOG SCALE;

EID: 77956922989     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2010.51.9.636     Document Type: Article

References (15)

1. Zimskind PD, Fetter TR, Wilkerson JL. Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 1967;97:840-4.
2. Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 2003;169:1065-9.
3. Pilcher JM, Patel U. Choosing the correct length of ureteric stent: a formula based on the patient's height compared with direct ureteric measurement. Clin Radiol 2002;57:59-62.
4. Al-Kandari AM, Al-Shaiji TF, Shaaban H, Ibrahim HM, Elshebiny YH, Shokeir AA. Effects of proximal and distal ends of double-J ureteral stent position on postprocedural symptoms and quality of life: a randomized clinical trial. J Endourol 2007;21:698-702.
5. Shibasaki M, Sudoh K, Inagaki O, Uchida W, Honda K. Effect of the optical isomers of YM-12617 on increased intra-urethral pressure induced by phenylephrine in anaesthetized dogs. J Auton Pharmacol 1992;12:263-8.
6. Chung DE, Te AE. Tolterodine extended-release for overactive bladder. Expert Opin Pharmacother 2009;10:2181-94.
7. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319-28.
8. Chew BH, Knudsen BE, Denstedt JD. The use of stents in contemporary urology. Curr Opin Urol 2004;14:111-5.
9. Thomas R. Indwelling ureteral stents: impact of material and shape on patient comfort. J Endourol 1993;7:137-40.
10. Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology 2006;67:35-9.
11. Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D'Armiento M. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol 2008;22: 651-6.
12. Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol 2009;181:170-6.
13. Wang CJ, Huang SW, Chang CH. Effects of tamsulosin on lower urinary tract symptoms due to double-J stent: a prospective study. Urol Int 2009;83:66-9.
14. Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-J stent-r elated symptoms. J Endourol 2009;23:1913-7.
15. Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG. Ureteral stent symptom questionnaire: development and validation of multidimensional quality of life measure. J Urol 2003;169:1060-4.